3D printing as a strategy to scale-up biohybrid hydrogels for T cell manufacture

Pérez del Río, Eduardo|||0000-0003-2444-5621; Rey Viñoles, Sergi|||0000-0002-2128-7704; Santos, Fabião; Castellote-Borrell, Miquel; Merlina, Francesca; Veciana Miró, Jaume; Ratera Bastardas, Imma; Mateos Timoneda, Miguel Ángel|||0000-0001-7657-1414; Engel López, Elisabeth|||0000-0003-4855-8874; Guasch, Judith

3D printing as a strategy to scale-up biohybrid hydrogels for T cell manufacture

The emergence of cellular immunotherapy treatments is introducing more efficient strategies to combat cancer as well as autoimmune and infectious diseases. However, the cellular manufacturing procedures associated with these therapies remain costly and time-consuming, thus limiting their applicabili...

Descripción completa

Detalles Bibliográficos
Autores:	Pérez del Río, Eduardo\|\|\|0000-0003-2444-5621, Rey Viñoles, Sergi\|\|\|0000-0002-2128-7704, Santos, Fabião, Castellote-Borrell, Miquel, Merlina, Francesca, Veciana Miró, Jaume, Ratera Bastardas, Imma, Mateos Timoneda, Miguel Ángel\|\|\|0000-0001-7657-1414, Engel López, Elisabeth\|\|\|0000-0003-4855-8874, Guasch, Judith
Tipo de recurso:	artículo
Fecha de publicación:	2024
País:	España
Institución:	Universitat Politècnica de Catalunya (UPC)
Repositorio:	UPCommons. Portal del coneixement obert de la UPC
Idioma:	inglés
OAI Identifier:	oai:upcommons.upc.edu:2117/416165
Acceso en línea:	https://hdl.handle.net/2117/416165 https://dx.doi.org/10.1021/acsami.4c06183
Access Level:	acceso abierto
Palabra clave:	3D printing 3D hydrogels T cells Cell therapy Cancer Hydrogels Layers scaffolds Suspensions Àrees temàtiques de la UPC::Enginyeria biomèdica::Biomaterials

id	ES_7f4da3ebd3774db3181ba6a9fe6993b4
oai_identifier_str	oai:upcommons.upc.edu:2117/416165
network_acronym_str	ES
network_name_str	España
repository_id_str
spelling	3D printing as a strategy to scale-up biohybrid hydrogels for T cell manufacturePérez del Río, Eduardo\|\|\|0000-0003-2444-5621Rey Viñoles, Sergi\|\|\|0000-0002-2128-7704Santos, FabiãoCastellote-Borrell, MiquelMerlina, FrancescaVeciana Miró, JaumeRatera Bastardas, ImmaMateos Timoneda, Miguel Ángel\|\|\|0000-0001-7657-1414Engel López, Elisabeth\|\|\|0000-0003-4855-8874Guasch, Judith3D printing3D hydrogelsT cellsCell therapyCancerHydrogelsLayers scaffoldsSuspensionsÀrees temàtiques de la UPC::Enginyeria biomèdica::BiomaterialsThe emergence of cellular immunotherapy treatments is introducing more efficient strategies to combat cancer as well as autoimmune and infectious diseases. However, the cellular manufacturing procedures associated with these therapies remain costly and time-consuming, thus limiting their applicability. Recently, lymph-node-inspired PEG–heparin hydrogels have been demonstrated to improve primary human T cell culture at the laboratory scale. To go one step further in their clinical applicability, we assessed their scalability, which was successfully achieved by 3D printing. Thus, we were able to improve primary human T cell infiltration in the biohybrid PEG–heparin hydrogels, as well as increase nutrient, waste, and gas transport, resulting in higher primary human T cell proliferation rates while maintaining the phenotype. Thus, we moved one step further toward meeting the requirements needed to improve the manufacture of the cellular products used in cellular immunotherapies.This research was funded by the Spanish Ministry of Science and Innovation (PID2020-115296RA-I00; PID2019-105622RB- I00; PID2021-128412OB-I00 European Union NextGeneratio- nEU/PRTR, and the “Ramó n y Cajal” program (RYC-2017- 22614)) as well as the Generalitat de Catalunya (SGRCat 2021- 00438; 2017-SGR-359; Tecnologies Emergents program of the General Directorate for Research − Nr. 001-P-001646, cofunded with FEDER Operational Program of Catalonia 2014−2020). The work was also supported by the Max Planck Society through the Max Planck Partner Group “Dynamic Biomimetics for Cancer Immunotherapy” in collaboration with the Max Planck Institute for Medical Research (Heidelberg, Germany). The authors are grateful for the financial support received from Instituto de Salud Carlos III through Consorcio Centro de Investigación Biomédica en Red (CIBER) with the project “Gels4ACT” (Nr. BBN20PIV02). This research was also supported by the European Union’s Horizon 2020 research and innovation program H2020-MSCA-COFUND-2016 (DOC- FAM, grant agreement Nr. 754397). The authors acknowledge financial support from the Spanish Ministry of Science and Innovation through the “Severo Ochoa” Program for Centres of Excellence in R&D (CEX2023-001263-S, CEX2019-000917-S and CEX2018-000789-S).Peer Reviewed20242024-01-0120242024-10-17journal articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/2117/416165https://dx.doi.org/10.1021/acsami.4c06183reponame:UPCommons. Portal del coneixement obert de la UPCinstname:Universitat Politècnica de Catalunya (UPC)Inglésengopen accesshttp://purl.org/coar/access_right/c_abf2Attribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:upcommons.upc.edu:2117/4161652026-05-27T15:37:01Z
dc.title.none.fl_str_mv	3D printing as a strategy to scale-up biohybrid hydrogels for T cell manufacture
title	3D printing as a strategy to scale-up biohybrid hydrogels for T cell manufacture
spellingShingle	3D printing as a strategy to scale-up biohybrid hydrogels for T cell manufacture Pérez del Río, Eduardo\|\|\|0000-0003-2444-5621 3D printing 3D hydrogels T cells Cell therapy Cancer Hydrogels Layers scaffolds Suspensions Àrees temàtiques de la UPC::Enginyeria biomèdica::Biomaterials
title_short	3D printing as a strategy to scale-up biohybrid hydrogels for T cell manufacture
title_full	3D printing as a strategy to scale-up biohybrid hydrogels for T cell manufacture
title_fullStr	3D printing as a strategy to scale-up biohybrid hydrogels for T cell manufacture
title_full_unstemmed	3D printing as a strategy to scale-up biohybrid hydrogels for T cell manufacture
title_sort	3D printing as a strategy to scale-up biohybrid hydrogels for T cell manufacture
dc.creator.none.fl_str_mv	Pérez del Río, Eduardo\|\|\|0000-0003-2444-5621 Rey Viñoles, Sergi\|\|\|0000-0002-2128-7704 Santos, Fabião Castellote-Borrell, Miquel Merlina, Francesca Veciana Miró, Jaume Ratera Bastardas, Imma Mateos Timoneda, Miguel Ángel\|\|\|0000-0001-7657-1414 Engel López, Elisabeth\|\|\|0000-0003-4855-8874 Guasch, Judith
author	Pérez del Río, Eduardo\|\|\|0000-0003-2444-5621
author_facet	Pérez del Río, Eduardo\|\|\|0000-0003-2444-5621 Rey Viñoles, Sergi\|\|\|0000-0002-2128-7704 Santos, Fabião Castellote-Borrell, Miquel Merlina, Francesca Veciana Miró, Jaume Ratera Bastardas, Imma Mateos Timoneda, Miguel Ángel\|\|\|0000-0001-7657-1414 Engel López, Elisabeth\|\|\|0000-0003-4855-8874 Guasch, Judith
author_role	author
author2	Rey Viñoles, Sergi\|\|\|0000-0002-2128-7704 Santos, Fabião Castellote-Borrell, Miquel Merlina, Francesca Veciana Miró, Jaume Ratera Bastardas, Imma Mateos Timoneda, Miguel Ángel\|\|\|0000-0001-7657-1414 Engel López, Elisabeth\|\|\|0000-0003-4855-8874 Guasch, Judith
author2_role	author author author author author author author author author
dc.subject.none.fl_str_mv	3D printing 3D hydrogels T cells Cell therapy Cancer Hydrogels Layers scaffolds Suspensions Àrees temàtiques de la UPC::Enginyeria biomèdica::Biomaterials
topic	3D printing 3D hydrogels T cells Cell therapy Cancer Hydrogels Layers scaffolds Suspensions Àrees temàtiques de la UPC::Enginyeria biomèdica::Biomaterials
description	The emergence of cellular immunotherapy treatments is introducing more efficient strategies to combat cancer as well as autoimmune and infectious diseases. However, the cellular manufacturing procedures associated with these therapies remain costly and time-consuming, thus limiting their applicability. Recently, lymph-node-inspired PEG–heparin hydrogels have been demonstrated to improve primary human T cell culture at the laboratory scale. To go one step further in their clinical applicability, we assessed their scalability, which was successfully achieved by 3D printing. Thus, we were able to improve primary human T cell infiltration in the biohybrid PEG–heparin hydrogels, as well as increase nutrient, waste, and gas transport, resulting in higher primary human T cell proliferation rates while maintaining the phenotype. Thus, we moved one step further toward meeting the requirements needed to improve the manufacture of the cellular products used in cellular immunotherapies.
publishDate	2024
dc.date.none.fl_str_mv	2024 2024-01-01 2024 2024-10-17
dc.type.none.fl_str_mv	journal article http://purl.org/coar/resource_type/c_6501 VoR http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv	info:eu-repo/semantics/article
format	article
dc.identifier.none.fl_str_mv	https://hdl.handle.net/2117/416165 https://dx.doi.org/10.1021/acsami.4c06183
url	https://hdl.handle.net/2117/416165 https://dx.doi.org/10.1021/acsami.4c06183
dc.language.none.fl_str_mv	Inglés eng
language_invalid_str_mv	Inglés
language	eng
dc.rights.none.fl_str_mv	open access http://purl.org/coar/access_right/c_abf2 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv	info:eu-repo/semantics/openAccess
rights_invalid_str_mv	open access http://purl.org/coar/access_right/c_abf2 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv	openAccess
dc.format.none.fl_str_mv	application/pdf
dc.source.none.fl_str_mv	reponame:UPCommons. Portal del coneixement obert de la UPC instname:Universitat Politècnica de Catalunya (UPC)
instname_str	Universitat Politècnica de Catalunya (UPC)
reponame_str	UPCommons. Portal del coneixement obert de la UPC
collection	UPCommons. Portal del coneixement obert de la UPC
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_	1869411813791105024
score	15,812429

3D printing as a strategy to scale-up biohybrid hydrogels for T cell manufacture

Similares en LA Referencia